Cytomegalovirus (HHV-5) Infections is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cytomegalovirus (HHV-5) Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cytomegalovirus (HHV-5) Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cytomegalovirus (HHV-5) Infections overview

Cytomegalovirus (CMV) is virus in the herpes family, also called HHV-5. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, and hearing, neurological, and developmental problems. The predisposing factors are direct contact with an infected surface or individual, weakened immune system, and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-virals and can be prevented by lifestyle modification.

For a complete picture of PTSR and LoA scores for drugs in Cytomegalovirus (HHV-5) Infections, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.